Table 1.

Showing Relationship of CKD to Mortality among Patients Undergoing Percutaneous Mitral Valve Replacement with Mitraclip.

Study	Endpoint	GFR<30	GFR 30-60	GFR<60
Rodrigo Estévez-Loureiro et al., 2015 Retrospective multicenter UK (n=173)	Mortality (up to 3 years)	HR 10 [1.7-58.4] p=0.011 (Cox analysis)
Yohei Ohno et al., 2016 Retrospective (GRASP registry) (n=214)	Composite of death surgery for mitral valve dysfunc. and MR grade >=3 at 12 months			HR 2.39 [1.19-4.78] p=0.014 (multivariate)
Kaneko et al., 2016 Retrospective single center Germany (n=206)	Mortality (up to 1000 days)	HR 4.322 [1.855-10.069] p=0.001 (multivariate)	HR 1.868 [0.949–3.679] p=0.071 (multivariate)
Toggweiler, Stefan et al., 2014 Retrospective MitraSWISS registry (n=74)	Mortality (up to 2 years)			HR 3.29 (1.37 to 7.92) p<0.01 (univariate)
Wang, Andrew et al., 2015 Retrospective EVEREST cohort (n=886)	Mortality (1 year)	HR 3.8 [2.38-6.05] (cox)	HR 2.35 [1.73–3.19] (cox)
Sha, Binita et al., 2018 Retrospective STS/ACC registry (n=5,241 based on creatinine clearance)	Mortality (30 day)	OR 1.63 [0.99-2.68] p=0.053 (cox)	OR 1.29 [0.78-2.12] p=0.32 (cox)
Sha, Binita et al., 2018 Retrospective STS/ACC registry (n=5,241 based on creatinine clearance)	Mortality (1-year)	2.6 [1.92-3.51] p<0.001 (cox)	2.9 [2.01-4.17] p<0.001 (cox)

CKD on long-term outcomes post transcatheter mitral valve repair.